Muscarinic receptor signaling contributes to atypical antipsychotic drug reversal of the phencyclidine-induced deficit in novel object recognition in rats

Abstract

Enhancement of cholinergic function via muscarinic acetylcholine receptor M₁ agonism improves cognition in some schizophrenia patients. Most atypical antipsychotic drugs, including clozapine and its active metabolite, N-desmethylclozapine, and lurasidone, enhance the release of acetylcholine in key brain regions involved in cognition (e.g. hippocampus). We determined the effect of muscarinic acetylcholine receptor M₁ stimulation on novel object recognition and its contribution to the ability of atypical antipsychotic drugs to reverse the novel object recognition deficit in rats withdrawn from subchronic phencyclidine, a rodent model of cognitive impairment in schizophrenia. In control rats, the non-specific muscarinic acetylcholine receptor antagonist, scopolamine, and the M₁ selective antagonist, VU0255035, induced a novel object recognition deficit, which was reversed by the M₁ agonist, AC260584. Scopolamine fully blocked the effect of clozapine and N-desmethylclozapine, but not lurasidone, to restore novel object recognition in subchronic phencyclidine-treated rats. VU0255035 also blocked these effects of clozapine and N-desmethylclozapine, but not lurasidone; however, the blockade was not as complete as that achieved with scopolamine. Furthermore, subchronic phencyclidine increased hippocampal M₁ mRNA expression. These data suggest that M₁ agonism is required for clozapine and N-desmethylclozapine to ameliorate the phencyclidine-induced deficit in novel object recognition, additional evidence that M₁ agonism is a potential target for treating cognitive impairment in schizophrenia.

Keywords

Muscarinic acetylcholine novel object cognition antipsychotics

Get full access to this article

View all access options for this article.

References

Alger

Nagode

Tang

(2014) Muscarinic cholinergic receptors modulate inhibitory synaptic rhythms in hippocampus and neocortex. Front Synaptic Neurosci 6: 18.

Alt

Pendri

Bertekap

Jr et al (2016) Evidence for classical cholinergic toxicity associated with selective activation of M1 muscarinic receptors. J Pharmacol Exp Ther 356: 293–304.

Anagnostaras

Murphy

Hamilton

et al (2003) Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 6: 51–58.

Andrus

Marable

Dunbar

et al (2007) Effects of intensity and type of prepulse stimulus on prepulse inhibition in scopolamine treated rats. Pharmacol Biochem Behav 87: 481–488.

Barak

(2009) Modeling cholinergic aspects of schizophrenia: Focus on the antimuscarinic syndrome. Behav Brain Res 204: 335–351.

Barak

Weiner

(2011a) The M(1)/M(4) preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: Putative efficacy against positive, negative and cognitive symptoms in schizophrenia. Int J Neuropsychopharmacol 14: 1233–1246.

Barak

Weiner

(2011b) Putative cognitive enhancers in preclinical models related to schizophrenia: The search for an elusive target. Pharmacol Biochem Behav 99: 164–189.

Berry

Engle

McIntosh

et al (2015) Alpha6-containing nicotinic acetylcholine receptors in midbrain dopamine neurons are poised to govern dopamine-mediated behaviors and synaptic plasticity. Neuroscience 304: 161–175.

Bradley

Lameh

Ohrmund

et al (2010) AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model. Neuropharmacology 58: 365–373.

10.

Burton

(2006) Symptom domains of schizophrenia: The role of atypical antipsychotic agents. J Psychopharmacol 20: 6–19.

11.

Bymaster

Heath

Hendrix

et al (1993) Comparative behavioral and neurochemical activities of cholinergic antagonists in rats. J Pharmacol Exp Ther 267: 16–24.

12.

Byne

White

Parella

et al (1998) Tardive dyskinesia in a chronically institutionalized population of elderly schizophrenic patients: Prevalence and association with cognitive impairment. Int J Geriatr Psychiatry 13: 473–479.

13.

Caroff

Davis

Miller

et al (2011) Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. J Clin Psychiatry 72: 295–303.

14.

Carruthers

Gurvich

Rossell

(2015) The muscarinic system, cognition and schizophrenia. Neurosci Biobehav Rev 55: 393–402.

15.

Cea-del Rio

Lawrence

Tricoire

et al (2010) M3 muscarinic acetylcholine receptor expression confers differential cholinergic modulation to neurochemically distinct hippocampal basket cell subtypes. J Neurosci 30: 6011–6024.

16.

Chew

Mulsant

Pollock

et al (2008) Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 56: 1333–1341.

17.

Chung

Dai

et al (2004) Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: Role of 5-HT1A receptor agonism. Brain Res 1023: 54–63.

18.

Cropley

Scarr

Fornito

et al (2015) The effect of a muscarinic receptor 1 gene variant on grey matter volume in schizophrenia. Psychiatry Res 234: 182–187.

19.

Davoren

Lee

Garnsey

et al (2016) Discovery of the potent and selective M1 PAM-agonist N-[(3R,4S)-3-hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)ben zyl]pyridine-2-carboxamide (PF-06767832): Evaluation of efficacy and cholinergic side effects. J Med Chem 59: 6313–6328.

20.

Dean

McLeod

Keriakous

et al (2002) Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 7: 1083–1091.

21.

Dencker

Thomsen

Wortwein

et al (2012) Muscarinic acetylcholine receptor subtypes as potential drug targets for the treatment of schizophrenia, drug abuse and Parkinson’s disease. ACS Chem Neurosci 3: 80–89.

22.

Dennis

Pasqui

Colvin

et al (2016) Activation of muscarinic M1 acetylcholine receptors induces long-term potentiation in the hippocampus. Cereb Cortex 26: 414–426.

23.

Desamericq

Schurhoff

Meary

et al (2014) Long-term neurocognitive effects of antipsychotics in schizophrenia: A network meta-analysis. Eur J Clin Pharmacol 70: 127–134.

24.

Desmarais

Beauclair

Margolese

(2012) Anticholinergics in the era of atypical antipsychotics: Short-term or long-term treatment? J Psychopharmacol 26: 1167–1174.

25.

Elvevag

Goldberg

(2000) Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 14: 1–21.

26.

Ennaceur

(2010) One-trial object recognition in rats and mice: Methodological and theoretical issues. Behav Brain Res 215: 244–254.

27.

Esclassan

Coutureau

Di Scala

et al (2009) A cholinergic-dependent role for the entorhinal cortex in trace fear conditioning. J Neurosci 29: 8087–8093.

28.

Ghoshal

Rook

Dickerson

et al (2016) Potentiation of M1 muscarinic receptor reverses plasticity deficits and negative and cognitive symptoms in a schizophrenia mouse model. Neuropsychopharmacology 41: 598–610.

29.

Gibbons

Dean

(2016) The cholinergic system: An emerging drug target for schizophrenia. Curr Pharm Des 22: 2124–2133.

30.

Gigout

Wierschke

Dehnicke

et al (2015) Different pharmacology of N-desmethylclozapine at human and rat M2 and M4 mAChRs in neocortex. Naunyn Schmiedebergs Arch Pharmacol 388: 487–496.

31.

Gould

Dencker

Grannan

et al (2015) Role for the M1 muscarinic acetylcholine receptor in top-down cognitive processing using a touchscreen visual discrimination task in mice. ACS Chem Neurosci 6: 1683–1695.

32.

Grayson

Leger

Piercy

et al (2015) Assessment of disease-related cognitive impairments using the novel object recognition (NOR) task in rodents. Behav Brain Res 285: 176–193.

33.

Green

Ellis

et al (2005) Muscarinic and nicotinic receptor modulation of object and spatial n-back working memory in humans. Pharmacol Biochem Behav 81: 575–584.

34.

Hagger

Buckley

Kenny

et al (1993) Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 34: 702–712.

35.

Hashimoto

(2015) Targeting of alpha7 nicotinic acetylcholine receptors in the treatment of schizophrenia and the use of auditory sensory gating as a translational biomarker. Curr Pharm Des 21: 3797–3806.

36.

Horiguchi

Huang

Meltzer

(2011) Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats. Psychopharmacology 217: 13–24.

37.

Huang

Panos

Kwon

et al (2014) Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: Role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism. J Neurochem 128: 938–949.

38.

Hui

Han

Yin

et al (2017) Association between DBH 19bp insertion/deletion polymorphism and cognition in schizophrenia with and without tardive dyskinesia. Schizophr Res 182: 104–109.

39.

Ichikawa

Dai

et al (2002) Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: Role of 5-HT1A receptor agonism. Brain Res 956: 349–357.

40.

Ishibashi

Yamazaki

Miledi

et al (2014) Nicotinic and muscarinic agonists and acetylcholinesterase inhibitors stimulate a common pathway to enhance GluN2B-NMDAR responses. Proc Natl Acad Sci USA 111: 12538–12543.

41.

Ishibashi

Horisawa

Tokuda

et al (2010) Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 334: 171–181.

42.

Javitt

(2012) Twenty-five years of glutamate in schizophrenia: Are we there yet? Schizophr Bull 38: 911–913.

43.

Jentsch

Taylor

(2001) Impaired inhibition of conditioned responses produced by subchronic administration of phencyclidine to rats. Neuropsychopharmacology 24: 66–74.

44.

Jentsch

Taylor

Roth

(1998) Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion. Neuropsychopharmacology 19: 105–113.

45.

Jones

Brady

Davis

et al (2008) Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci 28: 10422–10433.

46.

Jones

Byun

Bubser

(2012) Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology 37: 16–42.

47.

Keefe

(2008) Should cognitive impairment be included in the diagnostic criteria for schizophrenia? World Psychiatry 7: 22–28.

48.

Keefe

Bilder

Davis

et al (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 64: 633–647.

49.

Levey

Kitt

Simonds

et al (1991) Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci 11: 3218–3226.

50.

Bonhaus

Huang

et al (2007) AC260584 (4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one), a selective muscarinic M1 receptor agonist, increases acetylcholine and dopamine release in rat medial prefrontal cortex and hippocampus. Eur J Pharmacol 572: 129–137.

51.

Huang

Ichikawa

et al (2005) N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors. Neuropsychopharmacology 30: 1986–1995.

52.

Prus

Dai

et al (2009) Differential effects of M1 and 5-hydroxytryptamine1A receptors on atypical antipsychotic drug-induced dopamine efflux in the medial prefrontal cortex. J Pharmacol Exp Ther 330: 948–955.

53.

Snigdha

Roseman

et al (2008) Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine. Eur J Pharmacol 596: 89–97.

54.

Liao

Hong

Chen

et al (2003) Association of muscarinic m1 receptor genetic polymorphisms with psychiatric symptoms and cognitive function in schizophrenic patients. Neuropsychobiology 48: 72–76.

55.

Lustig

Sarter

(2016) Attention and the cholinergic system: Relevance to schizophrenia. Curr Top Behav Neurosci 28: 327–362.

56.

Maehara

Okuda

Ohta

(2011a) Ameliorative effect of N-desmethylclozapine in animal models of social deficits and cognitive functions. Brain Res Bull 86: 146–151.

57.

Maehara

Satow

Hikichi

et al (2011b) Antipsychotic effects of N-desmethylclozapine on sensorimotor gating function in rats–possible involvement of activation of M(1) muscarinic receptors. Eur J Pharmacol 667: 242–249.

58.

Mancama

Arranz

Landau

et al (2003) Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 119b: 2–6.

59.

Meltzer

(2015a) Attention must be paid: The association of plasma clozapine/NDMC ratio with working memory. Am J Psychiatry 172: 502–504.

60.

Meltzer

(2015b) Pharmacotherapy of cognition in schizophrenia. Curr Opin Behav Sci 4: 115–121.

61.

Meltzer

McGurk

(1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25: 233–255.

62.

Meltzer

Rajagopal

Huang

et al (2013) Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol 16: 2181–2194.

63.

Miyauchi

Neugebauer

Oyamada

et al (2016) Nicotinic receptors and lurasidone-mediated reversal of phencyclidine-induced deficit in novel object recognition. Behav Brain Res 301: 204–212.

64.

Newell

Zavitsanou

Huang

(2007a) Opposing short- and long-term effects on muscarinic M1/4 receptor binding following chronic phencyclidine treatment. J Neurosci Res 85: 1358–1363.

65.

Newell

Zavitsanou

Jew

et al (2007b) Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 31: 225–233.

66.

Nielsen

Levander

Kjaersdam Telleus

et al (2015) Second-generation antipsychotic effect on cognition in patients with schizophrenia-a meta-analysis of randomized clinical trials. Acta Psychiatr Scand 131: 185–196.

67.

Rajagopal

Massey

Huang

et al (2014) The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia. Curr Pharm Des 20: 5104–5114.

68.

Rajji

Mulsant

Davies

et al (2015) Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine. Am J Psychiatry 172: 579–585.

69.

Salavati

Rajji

Price

et al (2015) Imaging-based neurochemistry in schizophrenia: A systematic review and implications for dysfunctional long-term potentiation. Schizophr Bull 41: 44–56.

70.

Scarr

Cowie

Kanellakis

et al (2009) Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol Psychiatry 14: 1017–1023.

71.

Scarr

Udawela

Thomas

et al (2016) Changed gene expression in subjects with schizophrenia and low cortical muscarinic M1 receptors predicts disrupted upstream pathways interacting with that receptor. Mol Psychiatry. Epub ahead of print 1 November 2016. doi: 10.1038/mp.2016.195.

72.

Sheffler

Williams

Bridges

et al (2009) A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning. Mol Pharmacol 76: 356–368.

73.

Snigdha

Horiguchi

Huang

et al (2010) Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther 332: 622–631.

74.

Snyder

Greenberg

Yamamura

(1974) Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects. Arch Gen Psychiatry 31: 58–61.

75.

Steward

Kennedy

Morris

et al (2012) Chronic phencyclidine (PCP)-induced modulation of muscarinic receptor mRNAs in rat brain: Impact of antipsychotic drug treatment. Neuropharmacology 62: 1554–1563.

76.

Sur

Mallorga

Wittmann

et al (2003) N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci USA 100: 13674–13679.

77.

Tinsley

Fontaine-Palmer

Vincent

et al (2011) Differing time dependencies of object recognition memory impairments produced by nicotinic and muscarinic cholinergic antagonism in perirhinal cortex. Learn Mem 18: 484–492.

78.

Waddington

O’Callaghan

Larkin

et al (1993) Cognitive dysfunction in schizophrenia: Organic vulnerability factor or state marker for tardive dyskinesia? Brain Cogn 23: 56–70.

79.

Warburton

Brown

(2015) Neural circuitry for rat recognition memory. Behav Brain Res 285: 131–139.

80.

Weiner

Meltzer

Veinbergs

et al (2004) The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology 177: 207–216.

81.

Wess

(2004) Muscarinic acetylcholine receptor knockout mice: Novel phenotypes and clinical implications. Annu Rev Pharmacol Toxicol 44: 423–450.

82.

Woodward

Purdon

Meltzer

et al (2005) A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8: 457–472.

83.

Ball

Stoll

et al (2014) Direct excitation of parvalbumin-positive interneurons by M1 muscarinic acetylcholine receptors: Roles in cellular excitability, inhibitory transmission and cognition. J Physiol 592: 3463–3494.

84.

Zavitsanou

Katsifis

Mattner

et al (2004) Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 29: 619–625.

85.

Zavitsanou

Nguyen

Newell

et al (2008) Rapid cortico-limbic alterations in AMPA receptor densities after administration of PCP: Implications for schizophrenia. J Chem Neuroanat 36: 71–76.